United Kingdom-based ViiV Healthcare has filed a lawsuit against Gilead Sciences, alleging that bictegravir contained in the latter's triple combination HIV drug infringes patent covering dolutegravir in the US and Canada, it was reported on Friday.
The product is one of the three drugs utilised in Biktarvy, which received approval from the US Food and Drug Administration (FDA) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
According to the lawsuits filed in the US District Court for the District of Delaware and the Canadian Federal Court in Toronto, the company accused Gilead's bictegravir of not only infringing patent covering dolutegravir but also several other compounds that include the drug's unique chemical scaffold. The company stated that it will seek financial redress for the alleged patent infringement by Gilead's bictegravir.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT